Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

• Revenue in USD (TTM)0.00
• Net income in USD-29.80m
• Incorporated2017
• Employees28.00

• Location
  Sensei Biotherapeutics Inc1405 Research Blvd, Suite 125ROCKVILLE 20850United StatesUSA
• Phone+1 (240) 243-8000
• Fax+1 (302) 531-3150
• Websitehttps://www.senseibio.com/